title: Altered hypothalamus-pituitary-adrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome.
abstract: The human FMR1 gene contains an unstable CGG-repeat in its 5' untranslated region. The repeat length in the normal population is polymorphic (5-54 CGG-repeats). Individuals carrying lengths beyond 200 CGGs (i.e. the full mutation) show hypermethylation and as a consequence gene silencing of the FMR1 gene. The absence of the gene product FMRP causes the fragile X syndrome, the most common inherited form of mental retardation. Elderly carriers of the premutation (PM), which is defined as a repeat length between 55 and 200 CGGs, can develop a progressive neurodegenerative syndrome: fragile X-associated tremor/ataxia syndrome (FXTAS). The high FMR1 mRNA levels observed in cells from PM carriers have led to the hypothesis that FXTAS is caused by a pathogenic RNA gain-of-function mechanism. Apart from tremor/ataxia, specific psychiatric symptoms have been described in PM carriers with or without FXTAS. Since these symptoms could arise from elevated stress hormone levels, we investigated hypothalamic-pituitary-adrenal (HPA) axis regulation using a knock-in mouse model with an expanded CGG-repeat in the PM range (>98 repeats) in the Fmr1 gene, which shows repeat instability, and displays biochemical, phenotypic and neuropathological characteristics of FXTAS. We show elevated levels of corticosterone in serum and ubiquitin-positive inclusions in both the pituitary and adrenal gland of 100-week-old animals. In addition, we demonstrate ubiquitin-positive inclusions in the amygdala from aged expanded CGG-repeat mice. We hypothesize that altered regulation of the HPA axis and the amygdala and higher stress hormone levels in the mouse model for FXTAS may explain associated psychological symptoms in humans.
authors.affiliation: Department of Clinical Genetics, Erasmus MC, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.
authors.forename: J R
authors.initials: JR
authors.lastname: Brouwer
authors.forename: E
authors.initials: E
authors.lastname: Severijnen
authors.forename: F H
authors.initials: FH
authors.lastname: de Jong
authors.forename: D
authors.initials: D
authors.lastname: Hessl
authors.forename: R J
authors.initials: RJ
authors.lastname: Hagerman
authors.forename: B A
authors.initials: BA
authors.lastname: Oostra
authors.forename: R
authors.initials: R
authors.lastname: Willemsen
mesh_terms: D000223:Adaptation, Psychological / Q000502:physiology; D000818:Animals; D002524:Cerebellar Ataxia / Q000150:complications / Q000235:genetics / Q000503:physiopathology*; D003345:Corticosterone / Q000378:metabolism; D042622:DNA Repeat Expansion / Q000235:genetics*; D004195:Disease Models, Animal; D051860:Fragile X Messenger Ribonucleoprotein 1 / Q000235:genetics / Q000378:metabolism; D005600:Fragile X Syndrome / Q000150:complications / Q000235:genetics / Q000503:physiopathology*; D007030:Hypothalamo-Hypophyseal System / Q000378:metabolism / Q000503:physiopathology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D010913:Pituitary-Adrenal System / Q000378:metabolism / Q000503:physiopathology*; D025801:Ubiquitin / Q000378:metabolism
chemical_list: D003345:Corticosterone; D051860:Fragile X Messenger Ribonucleoprotein 1; D025801:Ubiquitin